Katie Quinn

Get more out of your business.

Reach it with Microsoft Dynamics 365 Business Central.

March 13, 2017 Katie Quinn

Biosimilars Forum Statement Regarding Nomination of Dr. Scott Gottlieb as Next Commissioner of the Food and Drug Administration

March 2, 2017 Katie Quinn

Past President of Biosimilars Forum Testifies before Congress Regarding BsUFA

January 17, 2017 Katie Quinn

Biosimilars Forum Statement Regarding FDA’s Draft Guidance for Industry on Interchangeability for Biosimilar Products

January 12, 2017 Katie Quinn

Biosimilars Forum Statement Regarding FDA’s Final Guidance on Nonproprietary Naming of Biosimilar Products

January 11, 2017 Katie Quinn

Biosimilars Forum Statement Regarding the CMS’ Treatment of Biosimilars Under the Medicaid Drug Rebate Program

November 1, 2016 Katie Quinn

Awareness of Biosimilars Among U.S. Specialty Physicians is High but New Survey Identifies Five Major Knowledge Gaps

October 20, 2016 Katie Quinn

Biosimilars Forum Submits comments on FDA Biosimilar Biological Product Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022

September 16, 2016 Katie Quinn

Biosimilars Forum Applauds Outcome of BsUFA Negotiations; Pleased to Have Played Important Role in Decision-Making

June 3, 2016 Katie Quinn

Biosimilars Forum Submits Comments in Response to FDA Draft Industry Guidance on Labeling for Biosimilar Products

March 31, 2016 Katie Quinn

Biosimilars Forum Issues Statement on FDA Draft Industry Guidance on Labeling for Biosimilar Products